Management trends in stage i testicular seminoma: Impact of race, insurance status, and treatment facility

Cancer

Volumn 121, Issue 5, 2015, Pages 681-687

  Gray, Phillip J ^a   Lin, Chun Chieh ^b   Sineshaw, Helmneh ^b   Paly, Jonathan J ^a   Jemal, Ahmedin ^b   Efstathiou, Jason A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

Chemotherapy; Practice patterns; Radiotherapy; Seminoma; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; HEALTH CARE FACILITY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MIDDLE AGED; OBSERVATION; ORCHIECTOMY; PATIENT CARE; PRIORITY JOURNAL; RACE DIFFERENCE; SEMINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TREND STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANCESTRY GROUP; CLINICAL PRACTICE; HEALTH CARE DISPARITY; INSURANCE; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TESTICULAR NEOPLASMS;

ADULT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONTINENTAL POPULATION GROUPS; HEALTHCARE DISPARITIES; HUMANS; INSURANCE COVERAGE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 84923275513     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29094     Document Type: Article

References (38)

1. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006; 367:754-765.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
3. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol. 2006; 24:5482-5492.
4. Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011; 29:4677-4681.
5. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011; 29:957-962.
6. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366:293-300.
7. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005; 23:1200-1208.
8. Choo R, Thomas G, Woo T, et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2005; 61:736-740.
9. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999; 17:1146.
10. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol. 1995; 13:2255-2262.
11. Warde PR, Gospodarowicz MK, Goodman PJ, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 1993; 27:11-15.
12. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992; 65:775-778.
13. Duchesne GM, Horwich A, Dearnaley DP, et al. Orchidectomy alone for stage I seminoma of the testis. Cancer. 1990; 65:1115-1118.
14. National Comprehensive Cancer Network. Testicular cancer. 2014 NCCN guidelines. http://www.nccn.org/professionals/physician-gls/pdf/testicular.pdf. Accessed March 8, 2014.
15. Steele GS, Richie JP, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999; 86:2171-2183.
16. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27:4177-4181.
17. Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013; 63:823-829.
18. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011; 185:72-78.
19. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15:683-690.
20. Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010; 28:4135-4141.
21. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010; 28:4649-4657.
22. Fossa SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007; 99:533-544.
23. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21:1513-1523.
24. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997; 89:1429-1439.
25. Jonker-Pool G, van Basten JP, Hoekstra HJ, et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. Cancer. 1997; 80:454-464.
26. Gordon W Jr, Siegmund K, Stanisic TH, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys. 1997; 38:83-94.
27. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol. 1993; 11:415-424.
28. Efstathiou JA, Paly JJ, Lu HM, et al. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012; 103:12-17.
29. Paly JJ, Efstathiou JA, Hedgire SS, et al. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013; 106:64-68.
30. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008; 26:3937-3942.
31. Huang LC, Ma Y, Ngo JV, Rhoads KF. What factors influence minority use of National Cancer Institute-designated cancer centers? Cancer. 2014; 120:399-407.
32. Lerro CC, Robbins AS, Fedewa SA, Ward EM. Disparities in stage at diagnosis among adults with testicular germ cell tumors in the National Cancer Data Base. Urol Oncol. 2014; 32:23.e15-23.e21.
33. Arvold ND, Catalano PJ, Sweeney CJ, et al. Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012; 84:383-389.
34. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20:4448-4452.
35. Kollmannsberger C, Tyldesley S, Moore C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011; 22:808-814.
36. Stenning S, Oliver T, Mead B, Gabe R. Carboplatin in clinical stage I seminoma: a valuable option for patient management. J Clin Oncol. 2011; 29:4210-4211.
37. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007; 25:4370-4378.
38. Krege S, Boergermann C, Baschek R, et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol. 2006; 17:276-280.